OQROSign up free
Politician trade (House)

Danaher Corporation (DHR): Rep. Julie Johnson (TX32) disclosed a sale $1K–$15K

Rep. Julie Johnson (TX32) disclosed a sale of Danaher Corporation in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
28 days
Disclosure lag
Traded
Dec 18, 2025
Disclosed
Jan 15, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Apr 28, 2025CongressDisclosed purchase of DHR — reported range $1,001 - $15,000
  2. Sep 25, 2025CongressDisclosed sale of DHR — reported range $1,001 - $15,000
  3. Oct 7, 2025CongressDisclosed purchase of DHR — reported range $1,001 - $15,000
  4. Oct 21, 2025Company filing · Form 8-K · ResultsReported its results
  5. Oct 31, 2025Insider · 1 personInsiders: 3 sales (~$129.6M)
  6. Nov 6, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 6, 2025, John T. Schwieters notified Danaher’s Board of Directors (“Board”) that he has decided not to stand for reelection at the Company’s 2026 annual meeting of shareholders (“2026 Annual Meeting”), and will retire from the Danaher Board as of the 2026 Annual Meeting.”
  7. Nov 10, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
  8. Nov 11, 2025InsiderCFO sold ~$3.47M of DHR shares in the open market
  9. Nov 12, 2025Insider · 2 peopleInsiders: 6 sales (~$100.3M)
  10. Nov 13, 2025CongressDisclosed partial sale of DHR — reported range $1,001 - $15,000
  11. Nov 17, 2025FDAFDA device clearance: Access Rubella IgG
  12. Nov 18, 2025InsiderDirector sold ~$747K of DHR shares in the open market
  13. Nov 25, 2025Insider · 1 personInsiders: 2 sales (~$9.4M)
  14. Nov 26, 2025FDARecall: Beckman Coulter UniCel Dxl 600, Part numbers: A71460, A71461, A30260; Immunoassay Method, Troponin Subunit
  15. Nov 26, 2025FDARecall: Beckman Coulter UniCel Dxl 800, Part numbers: 973100, A71456, A71457, A25288; Immunoassay Method, Troponin Subunit
  16. Dec 8, 2025FDARecall: The LDL-Cholesterol assay is comprised of two distinct phases. In phase one a unique detergent solubilizes cholesterol from non-LDL- lipoprotein particles. Thi…
  17. Dec 18, 2025 · this disclosureCongressDisclosed sale of DHR — reported range $1,001 - $15,000

What came next

  1. Dec 23, 2025FDARecall: CellMek SPS Sample Preparation System, REF: C44603, with software
  2. Jan 12, 2026Company filing · Form 8-K · ResultsReported its results
  3. Jan 16, 2026FDAFDA device clearance: Xpert GI Panel
  4. Jan 27, 2026FDAFDA device clearance: Access anti-HAV IgM
  5. Jan 28, 2026Company filing · Form 8-K · ResultsReported its results
  6. Jan 30, 2026FDARecall: CHEMISTRY ANALYZER AU5800, REF: B96697, B96698, B23279, B23280, B23281
  7. Jan 30, 2026FDARecall: DxC 700 AU, REF: B86444, B86446
  8. Jan 30, 20265% stakeThe Vanguard Group reported a passive stake (13G) of 8.6%
  9. Feb 5, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 5, 2026, Jessica L. Mega notified Danaher Corporation’s (“Danaher”) Board of Directors (“Board”) of her retirement from the Board as of February 5, 2026, due to commitments related to her other professional obligations.”
  10. Feb 19, 2026FDAFDA device clearance: Access anti-HBc Total
  11. Feb 19, 2026InsiderOfficer sold ~$275K of DHR shares in the open market
  12. Feb 20, 2026FDAFDA device clearance: Xpert Hemorrhagic Fever
  13. Mar 13, 2026FDAFDA device clearance: Access anti-HBc IgM
  14. Mar 16, 2026FDARecall: Access Total T4 Calibrator, Catalog No. 33805
  15. Mar 24, 2026FDAFDA device clearance: Access BNP II
  16. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  17. Apr 10, 2026FDAFDA device clearance: ABL90 FLEX PLUS System, safeCLINITUBES
  18. Apr 16, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Danaher Corporation

For Danaher Corporation, OQRO holds 14 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DHR page.

Other recent filings by Rep. Julie Johnson (TX32)

The full history of Rep. Julie Johnson (TX32) is on the profile page.

How this filing works

Explore the data

Other disclosures at Danaher Corporation

Everything OQRO holds on this company is on its DHR page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Sign up freeAlready have an account? Log in

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data